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Background: Recent evidence shows a selective destruction of the youngest circulating red
blood  cells (neocytolysis) trigged by a drop in erythropoietin levels.
Objective: The aim of this study was to evaluate the effect of recombinant human erythro-
poietin beta on the red blood cell storage lesion and apoptosis indices under blood bank
conditions.
Methods: Each one of ten red blood cell units preserved in additive solution 5 was divided in
two volumes of 100 mL and assigned to one of two groups: erythropoietin (addition of 665 IU
of  recombinant human erythropoietin) and control (isotonic buffer solution was added). The
pharmacokinetic parameters of erythropoietin were estimated and the following param-
eters  were measured weekly, for six weeks: Immunoreactive erythropoietin, hemolysis,
percentage of non-discocytes, adenosine triphosphate, glucose, lactate, lactate dehydroge-
nase, and annexin-V/esterase activity. The t-test or Wilcoxon’s test was used for statistical
analysis with signiﬁcance being set for a p-value <0.05.
Results: Erythropoietin, when added to red blood cell units, has a half-life >6 weeks under
blood bank conditions, with persistent supernatant concentrations of erythropoietin during
the  entire storage period. Adenosine triphosphate was higher in the Erythropoietin Group in
Week  6 (4.19 ± 0.05 mol/L vs. 3.53 ± 0.02 mol/L; p-value = 0.009). The number of viable cells
in  the Erythropoietin Group was higher than in the Control Group (77% ± 3.8% vs. 71% ± 2.3%;
p-value <0.05), while the number of apoptotic cells was lower (9.4% ± 0.3% vs. 22% ± 0.8%;
p-value <0.05).
Conclusions: Under standard blood bank conditions, an important proportion of red blood
cells  satisfy the criteria of apoptosis. Recombinant human erythropoietin beta seems to
improve storage lesion parameters and mitigate apoptosis.o Bra© 2015 Associac¸ã∗ Corresponding author at: Calle 114A, 56-25, Bogotá, Colombia.
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Introduction
During storage under blood bank conditions, red blood
cells (RBCs) undergo some deleterious changes that progres-
sively affect their metabolism, cytoskeleton and membrane.1,2
Within certain limits, several substances added during storage
improve and prolong the shelf life of RBCs by partially coun-
teracting this ‘storage lesion’. However, the exact nature of
this phenomenon and the precise combination of factors that
ideally preserves RBCs are still unknown.3
Plasma removal during preparation suddenly places RBCs
in a very different cellular environment that lasts the whole
period of storage; in particular, the absence of erythropoietin
(EPO), an essential cytokine that is associated to the viabil-
ity, proliferation and maturation of RBC precursors.4 Some
evidence shows that EPO not only maintains the viability of
the immature erythroid component, but is also linked to the
existence of mature RBC.5,6 In addition, mature RBCs can
undergo a rapid self-destruction process with several fea-
tures similar to apoptosis, including cell shrinkage, membrane
microvesiculation, changes in shape, cytoskeleton alterations
associated with protein degradation, and loss of cell mem-
brane phospholipid asymmetry, leading to the externalization
of phosphatidylserine.7,8
Now it is known that reticulocytes and young RBCs con-
tain more  EPO receptors than mature ones, suggesting that
young RBCs are very sensitive to changes in plasmatic levels of
EPO. Therefore, the number of EPO-binding sites may be a key
factor in the selection and survival of different RBC popula-
tions. The greater number of EPO-binding sites on young RBCs
could explain their preferential removal when EPO plasma lev-
els drop below a certain threshold.9 Thus, a sudden decrease
in EPO plasma concentration implies the selective destruc-
tion of the youngest circulating RBCs in a process named
neocitolysis.10
A model of enucleated cells maintained under some easily
accessible, manipulated and widely studied conditions, such
as in blood banks, would allow us to establish a relationship
between the phenomena of programmed cell death and the
RBC storage lesion, in the absence or presence of their putative
trophic factor, EPO. Therefore, if the storage lesion is a conse-
quence, in part, of the activation of the apoptotic phenomena,
the cytokine EPO could be a key factor that might reduce the
occurrence of this event.
This study evaluates the effect of recombinant human EPO
(rHuEPO) added to ten RBC units on some parameters mea-
sured during storage, including some apoptosis markers. From
the point of view of the blood bank, a beneﬁcial effect of
rHuEPO will reﬂect as a longer shelf life of RBCs with better
therapeutic beneﬁts and fewer associated complications.
Methods
Whole blood (450 mL ± 10%) was collected from ten volunteer
donors in citrate phosphate dextrose adenine (CPDA) antico-
agulant (63 mL). After separation of the plasma and buffy coat
by centrifugation, RBCs were suspended in 100 mL  of additive
solution 5 (AS-5) and were 90% leukodepleted. Once prepared,r. 2 0 1 6;3 8(1):15–20
each RBC unit was divided in two equal volumes: a dose of
665 IU of recombinant human erythropoietin beta (rHuEPO)
was added to one and 0.9% NaCl solution to the other as a
control. The mixtures were stored under standard blood bank
conditions (2–6 ◦C). After gentle mixing in a laminar ﬂow cab-
inet, 10 mL  samples were removed aseptically from each unit
at baseline (Week 0 of storage) and every two weeks thereafter
until Week 6 of storage.
The quantiﬁcation of the extracellular rHuEPO concentra-
tion was by the enzyme-linked immunosorbent assay (ELISA)
technique using a double antibody sandwich method (R&D
Systems, Inc., Minneapolis). Free hemoglobin in supernatant
was determined using the Hemocue Plasma/Low Hb tech-
nique. Hemolysis was calculated as the percentage of free
extracellular hemoglobin and the total hemoglobin present in
the sample. The formula used was:
Percent hemolysis =
(100 − hematocrit) × free plasma hemoglobin (g/dL)
Todal hemoglobin (g/dL)
Red cell morphology was evaluated by microscopy after
diluting samples in Dacie’s ﬂuid; cells were counted as normal
(discocytes) or anomalous (non-discocytes) and the propor-
tion of anomalous cells is expressed as a percentage. The RBC
adenosine triphosphate (ATP) concentration was estimated
using an enzymatic ultraviolet protocol (Sigma, St. Louis, MO).
Extracellular lactate, lactate dehydrogenase (LDH) and glucose
were measured using standard clinical chemistry methods
and reagents (Biosystems, Barcelona). All evaluations were
made on Weeks 0, 2, 4 and 6 of storage.
At the end of storage (Day 42), externalization of phos-
phatidylserine on the RBC membrane and esterase activity
were determined by 200 assays of annexin V and hydroly-
sis of 6-carboxyﬂuorescein diacetate (6-CFDA) by ﬂuorescence
microscopy (Sigma–Aldrich, St. Louis, Missouri). Brieﬂy, the
binding of annexin V to the cell membrane was visualized
by means of the annexin V-Cy3.18 conjugate, in which, on
using a green excitation ﬁlter (wavelength: 550 nm), the Cy3.18
functions as a ﬂuorochrome (red ﬂuorescence). The esterase
activity was visualized by the hydrolysis of 6-CFDA that, once
hydrolyzed, generates the ﬂuorescein ﬂuorochrome (green ﬂu-
orescence) using a blue-violet excitation ﬁlter (wavelength:
460 nm). Therefore, the following events can be seen with
each cell observed under a microscope: (1) Single green ﬂu-
orescence, indicating esterase activity, characteristic of viable
cells. (2) Single red ﬂuorescence in the membrane, indicating
annexin V bound to necrotic cells, and (3) green intracellular
ﬂuorescence and red ﬂuorescence in membrane characteristic
of cells undergoing apoptosis.
Statistics
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS) computer software (v.
13.0). Data are shown as means ± standard deviation (SD). The
t-test or Wilcoxon test were used to compare the Control and
rHuEPO Groups and between the readings taken at 2-week
intervals. P-values <0.05 were considered statically signiﬁcant.
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Table 1 – Pharmacokinetics of 665 IU recombinant
human erythropoietin added to red blood cell units
under blood bank conditions.
Parameter Value
Maximum concentration Cmax. (mIU/mL) 12,333.06
Volume of distribution (Vd) (mL) 54.08
Area under curve (AUC) 0  to  6 weeks (IU/mL) 324.42
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harmacokinetic data after adding rHuEPO to the RBC units
re shown in Table 1. Samples were obtained from RBC units
efore and immediately after adding the rHuEPO and weekly
hereafter for 6 weeks. The quantity of 665 IU of rHuEPO was
hosen to obtain 1000 times the physiological EPO concentra-
ion during RBC storage.
The EPO concentration before adding rHuEPO was
.35 mIU/mL. Half an hour after adding 665 IU of rHuEPO, the
ean concentration in the supernatant was 12.33 IU/mL. By
ultiexponential kinetic analysis, initially there was a quick
rop in the extracellular concentration of EPO followed by a
rogressive decrease with a tendency of stabilization at Week
 (9.16 IU/mL – 60% of the initial concentration). The concen-
ration remained roughly constant until Week 6 (Figure 1).
etabolic  changes  and  red  blood  cell  morphology  during
lood bank  storage
he amount of hemolysis increased gradually during stor-
ge in both groups, without exceeding at any moment the
aximum percentage allowed by the international quality
tandards (1%). There were no signiﬁcant differences between
he groups (p-value = 0.953).The percentage of non-discocytes increased progressively
uring storage in both rHuEPO and Control Groups from
.1% ± 0.07 and 0.2% ± 0.04 at Week 0, to 14.3% ± 1.1 and
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igure 1 – Erythropoietin concentration (mIU/mL): time
roﬁle after the administration of 665 IU to red blood cell
nits during blood bank storage.Figure 2 – Adenosine triphosphate concentration.
13.4% ± 1.3 at Week 6, respectively. There were no signiﬁcant
differences between the two groups at the end of the storage
(p-value = 0.172).
Red Cell ATP concentration (mol/g Hb) decreased progres-
sively in both groups during storage. However, the ATP concen-
tration was signiﬁcantly higher in the rHuEPO Group in Week
4 (5.05 ± 0.1 mol/L vs. 4.42 ± 0.08 mol/L; p-value = 0.017)
and Week 6 (4.19 ± 0.05 mol/L vs. 3.53 ± 0.02 mol/L; p-
value = 0.009) (Figure 2).
Extracellular lactate concentration increased progressively
during the storage. It was signiﬁcantly greater in the rHuEPO
Group in Week 4 (34.29 ± 1.7 mmol/L vs. 28.92 ± 1.3 mmol/L;
p-value = 0.04) and Week 6 (39.38 ± 1.9 mmol/L vs.
31.76 ± 1.1 mmol/L; p-value = 0.009) (Figure 3). Extracellu-
lar glucose concentration decreased progressively during
storage without signiﬁcant differences between the groups
(p-value = 0.646).
On the other hand, extracellular LDH activity increased
progressively during storage in both groups and in Week 6, it
was signiﬁcantly higher in the rHuEPO Group (304 ± 5.7 IU/mL
vs. 251 ± 8.3 IU/mL; p-value = 0.05).
Apoptosis  indices
Phosphatidylserine on the RBC membrane and the esterase
activity were investigated by ﬂuorescence microscopy at the
end of storage (6th week). The fraction of cells with green ﬂuo-
rescence, indicating esterase activity and characteristic of cell
viability, was signiﬁcantly higher in the rHuEPO Group com-
pared to the Control Group (77% ± 3.8% vs. 71% ± 2.3%; p-value
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Figure 3 – Lactate concentration.
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Figure 4 – Cell classiﬁcation after the 6th week of red blood
cell storage.
(approximately 6.5), and consequently the proteolytic action<0.05). The fraction of cells with red ﬂuorescence only (binding
of annexin V), characteristic of necrotic cells, was signiﬁcantly
lower in the Control Group compared with the rHuEPO Group
(6% ± 0.1% vs. 12% ± 0.6%; p-value <0.05). The cell fraction with
green and red ﬂuorescence, characteristic of cells undergoing
apoptosis was lower in the units exposed to rHuEPO compared
to the Control Group (9.4% ± 0.3% vs. 22% ± 0.8%; p-value <0.05)
(Figure 4).
Discussion
Native EPO possesses multiple physiologic roles such as the
stimulation of erythropoiesis, apoptosis rescue of astrocytes
and neurons, bone regeneration, the stimulation of mito-
sis in cardiomyocytes and endothelial cells, megakaryocyte
maturation, myeloid cell proliferation and tolerance of retina
photoreceptors to hypoxia mediated by nitric oxide (NO),
etc.11–13
The classic pattern of the actions of native EPO and rHuEPO
related to erythroid line cells is linked to survival, proliferation
and differentiation of committed stem cells [erythroid-burst
forming units (UFB), erythroid-colony forming units (UFC)].13
However, some evidence14 indicates that these substances
play a crucial role in the survival of mature circulating RBCs;
most of this evidence is constituted in the context of the phe-
nomenon of neocytolysis observed after an abrupt decrease
in plasma levels of native or recombinant EPO.15 On the other
hand, after the cessation of rHuEPO therapy, patients with
anemia of chronic kidney disease experienced enhanced RBC
death as soon as the EPO concentration declined.16
RBC units obtained and conserved under standard blood
bank conditions are almost free of extracellular EPO due to
the removal of blood plasma from the whole blood. Thus, it
is possible that, what is known as ‘storage lesion’ is, at least
in part, a reﬂection of the suppression of the effect of EPO on
mature RBCs.
For the ﬁrst time, this study shows the effects of the addi-
tion of rHuEPO to RBC units preserved under blood bank
conditions. The results of this study are split into two cate-
gories:r. 2 0 1 6;3 8(1):15–20
1. The pharmacokinetics of the addition of 665 IU of rHuEPO
to RBC units.
2. RBC storage lesion parameters (under blood bank condi-
tions) observed in the presence of rHuEPO.
The volume of immunoreactive rHuEPO (54.1 mL/dL) is
higher than the volume calculated (37.5 mL/dL) according to
the value of the hematocrit of RBC units (62.5%). Probably,
rHuEPO moved toward a second compartment, in this case the
RBC (adsorption by the cell membrane or entry into the intra-
cellular compartment), or, it could be interpreted as a quick
degradation of immunoreactive rHuEPO by proteases released
from the remaining viable leukocytes in the RBC unit.
Both mechanisms are not mutually excluding. In the ﬁrst
case, declining rHuEPO concentrations follow a multiexponen-
tial behavior; stabilization is achieved by the second week of
storage, in which the intracellular compartment would have
been saturated or the proteases that are present in the extra-
cellular medium would have lost their activity. In addition,
from this week there is no decrease in the rHuEPO concen-
tration, suggesting that its half-life is greater than six weeks.
On the other hand, it is remarkable that rHuEPO did not have
a deleterious effect on cell lysis parameters, hemolysis and
LDH, which always remained below the maximum permitted
limit according to international standards.17
It has been extensively documented that EPO acts on RBC
progenitors by binding to a speciﬁc receptor (EPOr) located
on the membrane, thus activating intracellular mechanisms
that impede apoptosis and maintain red cell line proliferation
and differentiation.18 The expression of EPOr during late ery-
throid development decreases exponentially, and it is claimed
that mature RBCs virtually have no EPOr and are EPO insensi-
tive. However, speciﬁc binding of EPO to human RBCs has been
reported,19 and some direct effects on mature RBCs have been
described such as glucose ﬂux,20 antioxidant defense,21 and
ion transportation.22
Previous research using 125I-EPO to track EPO binding to
human RBCs reported the presence of ﬁve to six EPO bind-
ing sites per cell, based on the assumption that the number
of speciﬁc EPO binding sites is equal for each RBC.22 The
marked decrease in EPO-binding capability with cell aging is
most likely achieved as the EPO receptor is released in vesi-
cles during cell maturation or undergoes internalization and
proteasomal degradation.23
Some evidence has shown the presence of a single class
of EPO binding sites, similar in afﬁnity and downstream tar-
gets to classic EPOr. EPO treatment results in upregulation of
RBC NO production via activation of the PI3K/Akt signaling
pathway and phosphorylation of RBC eNOS at Ser-1177.24
Additionally, there is evidence of a direct link between the EPO-
induced regulation of RBC eNOS activity and the maintenance
of the redox state in mouse RBCs. The increase in RBC-derived
NO would reduce the scavenging of NO by endothelial cells,
thereby facilitating NO-induced vasodilatation.25
With proteases in the extracellular medium, it is impor-
tant to remember that the pH of the medium is slightly acidic
26on EPO is reduced. Additionally, rHuEPO is a peptide, which
could diminish the access of proteases. In fact, in vivo, the
highly glycosylated rHuEPO has a longer half-life than native
oter. 
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PO.27 On the other hand, unless proteolysis of the sequence of
pitopes recognized by the antibodies used in the ELISA tech-
ique occurs, immunoreactive rHuEPO will not be detected.
Intracellular concentrations of ATP had a similar behav-
or in both groups (rHuEPO and control). However, in Weeks
 and 6 of storage, the RBC ATP concentration was signiﬁ-
antly higher in the rHuEPO Group than the Control Group.
his result suggests that rHuEPO, through its receptor, is able
o modify the energy metabolism of RBCs. In addition, rHuEPO
iminishes the magnitude of one of the key indicators of stor-
ge lesion, ATP depletion.28 This smaller drop in intracellular
TP can be explained in two ways: ﬁrst, rHuEPO diminishes
he consumption of ATP and second, at 4 ◦C this cytokine
timulates ATP production, or both. RBC ATP concentrations
aintain cell viability and normal ﬂow characteristics, caus-
ng local vasodilatation in the microcirculation.
The percentage of hemolysis was statistically similar in the
wo groups. This increase did not exceed the international
uality standards (<1%) at any time. Hence, rHuEPO did not
ause cell destruction. However, it cannot be assumed that
imilar proportions of hemolysis means similar mechanisms
f destruction: apoptosis or necrosis (see below).
The extracellular lactate concentration progressively
ncreased in both groups over the period of storage. There-
ore, even at 4 ◦C, glucose is depleted by the glycolytic pathway.
owever, in Weeks 4 and 6 of storage, lactate concentration
as signiﬁcantly higher in the rHuEPO Group, which means
hat during the storage period there was a signiﬁcantly higher
roduction of lactate in this group. This can be interpreted
n two  ways: ﬁrst, there is a higher availability of the sub-
trate (glucose) for the glycolytic pathway in the units with
HuEPO; second, glucose consumption in the glycolytic path-
ay is more  efﬁcient in the presence of rHuEPO as reﬂected
n a higher lactate production. Then, rHuEPO is able to avoid,
n part, the deterioration in the glycolytic pathway, which is
he only physiologic mechanism that mature RBCs possess to
roduce ATP.
There was a progressive increase in LDH activity during
torage in both groups. However, in Week 6, this activity was
igniﬁcantly higher in the rHuEPO Group. LDH leakage to the
xtracellular space can be explained in two ways: ﬁrst, a rise
n hemolysis in RBCs exposed to rHuEPO (this possibility was
iscarded because of the results of hemolysis). Second, as is
iscussed below, the percentage of necrotic cells in the rHuEPO
roup was higher.
The annexin V and esterase activity showed that, under
torage conditions at 4 ◦C, rHuEPO is able to signiﬁcantly
mprove cell viability; this fact is correlated to higher levels
f ATP and lactate production. Additionally, under these con-
itions, treatment with rHuEPO decreased the proportion of
ells that satisfy the two criteria for apoptosis by ﬂuorescence
icroscopy, the appearance of phosphatidylserine on the RBC
embrane and esterase activity.
Although the classic approaches of apoptosis deﬁned for
ucleated cells are not completely applicable to mature RBCs,
 lot of evidence accumulated in the last few years indicates
hat mature RBCs are probably ‘mummiﬁed’, culminating a
rocess of programmed death at the end of their physiologic
eriod of life in the circulation.29 However, there is no previous
ublished evidence about the course of this peculiar process of2 0 1 6;3 8(1):15–20 19
apoptosis or ‘eryptosis’ and the conditions of prolonged aging
achieved during storage in blood bank conditions. Here, it is
necessary to keep in mind that, at the end of 6 weeks of storage
in AS-5, 1/120 of the cells have an age of almost 162 days, which
is higher than the maximum age reached in vivo.7
This study shows for the ﬁrst time that, under standard
blood bank conditions, an important proportion of RBCs sat-
isfy the criteria of apoptosis, indicating that the preservation
conditions/solutions used, do not prevent this phenomenon,
and that this is associated with the short lifespan of trans-
fused RBCs. Therefore, it is interesting that the addition of
rHuEPO can signiﬁcantly reduce the proportion of RBC sat-
isfying the characteristics for apoptosis, thus opening the
discussion about the improved preservation of these cells in
an EPO-enriched media.
However, the effects of rHuEPO were accompanied by a
higher proportion of necrotic cells, which can be interpreted
in two ways: ﬁrst, rHuEPO may modulate the ﬁnal behavior
of RBCs, diverting their behavior from apoptosis to necrosis,
or second, rHuEPO induces cell necrosis. This latter event has
not been documented in previous studies (in vivo or in vitro)
in respect to different cell types using native EPO or rHuEPO.
In spite of this fact, it is interesting that the number of viable
cells was higher in the rHuEPO Group.
RBC apoptosis or eryptosis during blood bank storage can
be a direct consequence of oxidative stress and caspase-
mediated fragmentation involving the loss of band 3 protein
thereby starting a process of immune recognition and phago-
cytic removal of senescent and impaired RBC from circulation.
In addition, it was reported that EPO was able to protect the
RBC membrane from oxidative damage (lipid peroxidation) by
scavenging hydroxyl radicals. Indeed, EPO was able to inhibit
the externalization of phosphatidylserine in a model of oxida-
tive stress presumably via the EPOr.30
Conclusions
Future studies are necessary to identify the minimum dose
of EPO needed to achieve the desirable effects of increases
in the proportion of viable cells and decreases in apoptotic
cells, keeping in mind that, the increment in the proportion
of viable cells is accompanied by a signiﬁcant improvement of
key parameters related to the RBC storage lesion.
The mechanisms involved in the death of circulating RBCs
as well as those related to increased survival are of great inter-
est because, apart from their association to the treatment of
anemia, storage conditions in blood banks will be improved by
increasing the shelf life and quality of stored RBCs, with better
clinical beneﬁts for patients.
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